135
Views
12
CrossRef citations to date
0
Altmetric
Original Article

Immunohistochemical Analysis of Orbital Connective Tissue Specimens of Patients With Active Graves Ophthalmopathy

, , , , , & show all
Pages 631-638 | Received 02 Jul 2004, Accepted 22 Dec 2004, Published online: 02 Jul 2009
 

Abstract

Purpose: To explore the immune mechanism of Graves ophthalmopathy (GO) by analyzing infiltrating cells in orbital connective tissue (OCT) specimens of patients with active GO using immunohistochemical methods. Methods: Five OCT specimens obtained from patients with active GO and five control specimens obtained from forensic cadavers who died from nonmedical reasons were stained with anti-CD3, CD4, CD8, CD45RO, HLA-Dr, CD25, and TNF-α monoclonal antibodies. Positively stained cells were counted and results were interpreted as cell counts/mm2. Four of five GO patients had never been treated with any immunomodulating therapy. Only one had received oral prednisolone prior to tissue sampling, but this treatment had ceased 5 months before surgery. Results: The retro-orbital tissue specimens obtained from forensic cadavers did not show any significant positive staining for any monoclonal antibody tested. However, the specimens from GO patients showed positively stained means of 36.66 ± 4.61 HLA-Dr+, 12.8 ± 3.42 CD8+, 11.8 ± 1.78 CD4+, 16.6 ± 1.81 CD3+, 21.2 ± 3.12 CD45RO+, 10.4 ± 2.07 TNF-α+, 7.2 ± 1.48 CD25+, 3.2 ± 1.09 CD4+CD8+, 4.6 ± 1.67 CD4+CD45RO+, 2.8 ± 0.83 CD8+CD45RO+, 1.6 ± 0.89 CD4+CD25+, and 1.8 ± 1 0.83 CD8+CD25+ cells/mm2. Conclusions: Our study supports that most of the infiltrating lymphocytic cells in the active stage of GO are T cells, and a significant proportion of them are CD45RO+ cells. Infiltration of OCT by HLA-Dr+, CD25+, and TNF-α cells suggests that Th1-type immune reaction with the interference of proinflammatory cytokine(s) (TNF-α) may be important in the pathogenesis of disease. Further studies are needed to understand the disease pathogenesis and may provide a scientific basis for future treatment alternatives for the disease (e.g., anticytokine treatment).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.